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Summary
Cancer is a heterogeneous disease with diverse molecular etiologies and outcomes.
The Cancer Genome Atlas (TCGA) has released a large compendium of over
10,000 tumors with RNA-seq gene expression measurements. Gene expression
captures the diverse molecular profiles of tumors and can be interrogated to reveal
differential pathway activations. Deep unsupervised models, including Variational
Autoencoders (VAE) can be used to reveal these underlying patterns. We compare
a one-hidden layer VAE to two alternative VAE architectures with increased depth.
We determine the additional capacity marginally improves performance. We train
and compare the three VAE architectures to other dimensionality reduction tech-
niques including principal components analysis (PCA), independent components
analysis (ICA), non-negative matrix factorization (NMF), and analysis of gene
expression by denoising autoencoders (ADAGE). We compare performance in a
supervised learning task predicting gene inactivation pan-cancer and in a latent
space analysis of high grade serous ovarian cancer (HGSC) subtypes. We do not
observe substantial differences across algorithms in the classification task. VAE
latent spaces offer biological insights into HGSC subtype biology.
1 Introduction
From a systems biology perspective, the transcriptome can reveal the overall state of a tumor [1].
This state involves diverse etiologies and aberrantly active pathways that act together to produce
neoplasia, growth, and metastasis [2]. Such patterns can be extracted with machine learning.
Deep generative models have improved state of the art in several domains including image and text
processing [3–5]. Such models can simulate realistic data by learning an underlying data generating
manifold. The manifold can be mathematically manipulated to extract interpretable elements from
the data. For example, a recent imaging study subtracted the vector representation of a “neutral
woman” from a “smiling woman”, added the result to a “neutral man”, and revealed image vectors
representing “smiling men” [6]. In text processing, ~king − ~man+ ~woman = ~queen [7].
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Previously, nonlinear dimensionality reduction approaches have revealed complex patterns and novel
biology from publicly available gene expression data [8, 9], including drug response predictions [10].
Here, we extend a one-hidden layer VAE model, named Tybalt [11]. We train and evaluate Tybalt,
plus two other VAE architectures and compare them to other dimensionality reduction algorithms.
2 Methods
2.1 The Cancer Genome Atlas RNAseq Data
We used TCGA PanCanAtlas RNA-seq data from 33 different cancer-types [12]. The data includes
10,459 samples (9,732 tumors and 727 tumor adjacent normal). The data was batch corrected and
RSEM preprocessed, and is in the log2(FPKM + 1) format. To facilitate VAE training, we zero-one
normalized by gene. We also used zero-one normalization for NMF and ADAGE. We used z-scored
data for PCA and ICA. All data are publicly available and were accessed from the UCSC Xena
browser under a versioned Zenodo archive [13].
2.2 Variational Autoencoder Training
We trained VAE models as previously described [11]. We performed a grid search over hyperpa-
rameters and defined optimal models by lowest holdout validation loss. VAE loss is the sum of
reconstruction loss and a Kullback-Leibler (KL) divergence term constraining feature activations to a
Gaussian distribution [3, 4]. We searched over batch sizes, epochs, learning rates, and kappa values.
Kappa controls “warmup”, which determines how quickly the loss term incorporates KL divergence
[14]. VAEs learn two distinct latent representations, a mean and a standard deviation vector, which
are reparametrized into a single vector that can be back-propagated. This enables rapid sampling over
features to simulate data.We trained our models using Keras [15] with a TensorFlow backend [16].
We trained and evaluated the performance of three VAE architectures (Table 1). Using an EVGA
GeForce GTX 1060 GPU, all VAE models were trained in under 4 minutes.
Table 1: VAE Architectures
Name Hidden Layers Hidden Layer Size Latent Feature Size
Tybalt 1 100
Two Hidden VAE (100) 2 100 100
Two Hidden VAE (300) 2 300 100
2.3 Dimensionality Reduction Analysis
We evaluated the ability of the VAE models to generate biologically meaningful features. We
compared these features to PCA, ICA, NMF, and ADAGE features derived from the same pan-cancer
RNAseq data.
2.3.1 Predicting NF1 inactivation in tumors from gene expression data
Molecular aberrations in cancer form gene expression signatures that supervised machine learning
algorithms can detect [17, 18]. We trained elastic net logistic regression classifiers to detect pan-
cancer tumors with inactivated NF1. We defined NF1 inactivated tumors based on the presence
of deleterious NF1 mutations or NF1 deep copy number loss. NF1 inactivation is difficult but
important to detect because NF1 can be inactivated by multiple mechanisms and reliable classification
is required for effective targeted therapies [19]. We trained independent models using pan-cancer
RNAseq features derived from each dimensionality reduction algorithm. We report performance
during 5-fold cross validation. We performed all training and evaluation using sci-kit learn [20]. We
trained our models using tumors that had matched mutation, copy number, and RNAseq data, and we
used only cancer-types that had greater than 10 NF1 inactivated samples (n = 1774). This included
bladder carcinoma (BLCA), low grade glioma (LGG), lung adenocarcinoma (LUAD), paraganglioma
and pheochromocytoma (PCPG), skin cutaneous melanoma (SKCM), and stomach adenocarcinoma
(STAD). As a negative control, we shuffled gene expression profiles for each sample independently,
and used these shuffled matrices for predictions.
2
2.3.2 High grade serous ovarian cancer arithmetic
Four HGSC subtypes have been previously described [21]. However, they are not consistent across
populations [22]. Using original TCGA subtype labels [23], we calculated mean HGSC subtype
vector representations for the mesenchymal and immunoreactive subtypes with the latent space
representation from each dimensionality reduction algorithm. Samples from the two subtypes were
often aggregated under different clustering initializations [22]. The mesenchymal subtype is defined
by poor prognoses, overexpression of extracellular matrix genes, and increased desmoplasia, while
the immunoreactive subtype displays increased survival and immune cell infiltration [24, 25]. We
hypothesized that subtracting latent space representations of subtypes would reveal biological patterns.
To characterize the patterns, we performed pathway overrepresentation analyses (ORA) [26] over
Gene Ontology (GO) terms [27] using the high weight genes (> 2.5 standard deviations from the
mean) of the highest differentiating positive feature. We report the most significantly overrepresented
GO term.
3 Results
3.1 Modest improvements by architecture
We observed increased performance for the two-hidden layer models, and an additional increase
for the model with two compression steps. However, the benefits were modest as compared to the
one-hidden layer Tybalt model (Figure 1).
Figure 1: Evaluating three VAE architectures reveals modest performance improvements for deeper
models. Models were selected based on lowest holdout validation loss at training end. Training was
relatively stable for many hyperparameter combinations. Random fluctuations and selection bias
cause validation loss to appear, counterintuitively, lower than training loss.
3.2 Dimensionality Reduction Comparison
3.2.1 Supervised classification of NF1 inactivation
Based on receiver operating characteristic (ROC) curves, all algorithms had relatively similar perfor-
mance (Figure 2A). PCA performed slightly better than other dimensionality reduction algorithms
(area under the ROC curve (AUROC) = 65.6%). However, raw gene expression features performed
the best (AUROC = 68.4%). There were more classification features used for models built with
raw features as compared to other methods; NMF included many features where PCA included the
fewest (Figure 2B). The shuffled dataset contained the highest number of features, and was somewhat
predictive of NF1 status (AUROC = 55.4%), which may be an artifact of relatively low sample sizes.
3.2.2 Latent space arithmetic of HGSC subtypes
We ranked mean activation differences across dimensionality reduction methods (Figure 3). PCA
included the largest number of features with high values, while ICA and NMF had few activation
differences. The nonlinear neural network based approaches displayed sparse feature differences.
ORA analyses revealed few significant terms in the linear methods (Table 2). Of the nonlinear
methods, Tybalt, and the 300-hidden node VAE both identified a collagen term, which is known to be
associated with mesenchymal subtype tumors [24].
3
Figure 2: Evaluating dimensionality reduction algorithms in predicting NF1 inactivation pan-cancer.
(A) Receiver operating characteristic curve for cross validation intervals. (B) Number of features
selected by each model. The colors are consistent between figure panels.
Figure 3: Subtracting mean vector representations of the Mesenchymal and Immunoreactive High
Grade Serous Ovarian Cancer (HGSC) subtypes.
Table 2: Dimensionality reduction algorithms subtraction comparison
Algorithm Top Pathway Adj. p value
PCA Zero high weight genes
ICA No significant pathways
NMF Homophilic Cell Adhesion Via Plasma Membrane Adhesion Molecules 3.3e−06
ADAGE No significant pathways
Tybalt Collagen Catabolic Process 1.8e−09
VAE (100) Epidermis Development 8.0e−04
VAE (300) Collagen Catabolic Process 1.7e−03
4 Conclusions
We evaluated the performance of three VAE models trained on TCGA pan-cancer gene expression.
While we did not explore larger architectures with higher capacity, it appears that increasing the depth
of model only modestly improves performance. It is also likely that increasing model depth reduces
the ability to interpret the model. We also did not compare performance across different sized latent
spaces. Nevertheless, we show that VAEs capture signals that are able to predict gene inactivation
comparably to other algorithms. We demonstrate that the VAE latent space arithmetic provides a
unique benefit and should be explored further in the context of gene expression data. We provide
source code to reproduce training and latent space analyses at https://github.com/greenelab/tybalt
[28] and pan-cancer classifier analyses at https://github.com/greenelab/pancancer [29].
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